Share
Download
Cite
+ Favorites
Share
Download
Cite
+ Favorites
RESEARCH
Remdesivir As the First FDA-approved COVID-19 Treatment: An Updated Review and Meta-analysis .
OrthoEvidence Journal (OE Journal) - OE Original
OE Journal. 2020;8(21):1Remdesivir became the first FDA-approved COVID-19 treatment in late 2020, driven by early RCTs suggesting quicker recovery in hospitalized patients. But when all high-quality evidence is considered, the picture is far more mixed. Large trials such as WHO’s SOLIDARITY study show no meaningful effect on mortality, ventilation, or hospital stay. Smaller trials report modest improvements—mainly a 2–3 day reduction in time to clinical improvement—without affecting survival. Serious adverse events appear slightly less common with remdesivir, but overall benefits are small and uncertain. Emerging evidence underscores that remdesivir is not a cure and offers limited clinical impact, especially once large, pragmatic trials are factored in.
Already have an account? Log in
Part of an association? Click here, you may already have full access!
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
